In this respect, studies started to evaluate SNP in IL-23R, showing that perturbations in IL-23 signaling pathways lead to pathophysiological changes which may be the ground for the development of autoimmune diseases such as MS, IBD, psoriasis, RA and AS [54,55]. This evidence concerns the gene IL37 and myeloid sarcoma.